Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06225973 · ClinicalTrials.gov registry record · Phase 2
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
A Phase 2 study of Dry Eye Disease, sponsored by Telios Pharma.
- Active
- Registry status
- Phase 2
- Development phase
- 880
- Enrollment target
- 18
- Study locations
NCT06225973: Active Phase 2 study of Dry Eye Disease, sponsored by Telios Pharma.
NCT06225973 is a Phase 2 study of Dry Eye Disease that is active but no longer recruiting, run by Telios Pharma. The registered enrollment target is 880 participants, above the 228-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (286% higher). The trial reports 18 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06225973, a Phase 2 study of Dry Eye Disease, is active but no longer recruiting, sponsored by Telios Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 880 participants
- Enrollment target
- 18
- Study locations
Study Summary
In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or vehicle as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: a two-week screening phase/run-in and a six-week double-masked treatment phase.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG TL-925
Study Locations (18)
Massachusetts
- Andover Eye Associates - Andover - Andover
- Andover Eye Associates - Raynham - Raynham
- NEERA - Westborough - Westborough
- NEERA - Woburn - Woburn
California
- Global Research Management - Glendale
- Nvision - La Mesa - La Mesa
- Nvision - Torrance - Torrance
Tennessee
- Advancing Vision Research - Goodlettsville
- Total Eye Care, PA - Memphis
- Advancing Vision Research - Smyrna
North Carolina
- Oculus Research - Garner
- Wilmington Eye - Leland
Arizona
- Cornea and Cataract Consultants of Arizona - Phoenix
Illinois
- Wyse Eyecare - Northbrook
Indiana
- Pankratz Eye - Columbus
Kentucky
- Butchertown Clinical - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 2024-02-06 |
| Est. Completion | 2024-12 |
| Phase | Phase 2 |
What the registry record for NCT06225973 still lists
NCT06225973 is an interventional study that assigns participants to a tested intervention. The registered 880 participants enrollment target is mid-sized for trials with a published cap, above the 228-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (286% higher).
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06225973 lists 18 locations in 10 states (Massachusetts, California, Tennessee).
Frequently Asked Questions
What is clinical trial NCT06225973 about?
NCT06225973 is a clinical study titled "A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease". In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or vehicle as topical ophthalmic eye drops administered bil...
What is the current status of trial NCT06225973?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 880 participants. The study started on 2024-02-06. Estimated completion is 2024-12.
What conditions does trial NCT06225973 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT06225973?
The interventions under investigation include: Placebo (OTHER), TL-925 (DRUG).
Who is sponsoring clinical trial NCT06225973?
This trial is sponsored by Telios Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06225973 being conducted?
This trial has 18 study locations across Arizona, California, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06225973's enrollment target sits among peer trials
880 2nd of 33 the highest of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
-
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
COMPLETED · Phase 2
-
A Study of TL-925 as a Treatment for Dry Eye Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
- NCT06580314 · 880 participants · Phase 3
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI